BIODIEM TO BEGIN DIABETIC BLINDNESS TRIAL

A A

BioDiem has received regulatory approval to begin a Phase I/II clinical trial for its peptide BDM-E in patients with diabetic macula oedema, a leading cause of blindness.

BDM-E is a potential treatment for the two major causes of blindness -- diabetic retinopathy and age-related macular degeneration. It is a small synthetic peptide that can stimulate growth of new retinal pigmented epithelial cells and inhibits the growth of choroidal endothelial cells associated with unwanted neovascularisation.